Tirzepatide's dual mechanism targets GIP and GLP-1, so it provides strong cardiovascular benefits, said Stephen Nicholls, MBBS, PhD, MBA.
Stephen Nicholls, MBBS, PhD, MBA
Advertisement
Stephen Nicholls, MBBS, PhD, MBA, is a professor of cardiology at Monash University, the program director of the Victorian Heart Hospital at Monash Health, and the director of the Monash Victorian Heart Institute in Melbourne, Australia.
Articles by Stephen Nicholls, MBBS, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Integrating Sotatercept Into PAH Care: Vallerie McLaughlin, MD
2
Eosinophilia Linked With Immune-Related Adverse Events in NSCLC Treatment
3
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
4
Bridging the Gap Between Cutting-Edge Cancer Care and Equitable Access
5
